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Chloroquine	and	mefloquine	have	superior	
safety	profiles	in	pregnancy,	though	all	
antimalarials	are	effective	for	prophylaxis.	
antimalarials	will	decrease	the	severity	of	
maternal	malaria	infection	and	malaria-
associated	anemia,	while	decreasing	the	
incidence	of	low	birth	weight	and	perinatal	
death	in	women	having	their	first	or	
second	baby	(strength	of	recommendation	
[sor]:	A,	based	on	systematic	review	of	
consistent,	good-quality	patient-oriented	
evidence).	
	 you	can	determine	malaria	risk	and	
sensitivity	of	Plasmodium species	by	country	
at	wwwn.cdc.gov/travel/destinationlist.
aspx.1	urge	women	to	delay	travel	until	after	
pregnancy	if	possible2	(sor:	C,	based	on	
patient-oriented	expert	opinion).
Don’t forget to discuss mosquito netting 
and insect repellant
adverse	outcomes	associated	with	malaria	
during	pregnancy	include	restricted	fetal	
growth,	low	birth	weight,	preterm	delivery,	
congenital	infection,	spontaneous	abortion,	
and	perinatal	death.	you	should	counsel	
travelers	to	avoid	travel	to	areas	where	
malaria	is	endemic	during	pregnancy.	
For	those	who	are	unable	to	avoid	
travel,	or	who	reside	in	malaria-endemic	
areas	during	pregnancy,	physicians	should	
focus	not	only	on	chemoprophylaxis,	but	
provide	verbal	and	written	counsel	regarding	
malaria	personal	protection	measures.	
Because	mosquitoes	usually	feed	at	night,	
travelers	should	remain	within	screened	
areas	after	dusk,	use	permethrin-treated	
bed	nets,	wear	protective	clothing,	and	
apply	insect	repellant.	advise	patients	who	
travel	to	malaria-endemic	areas	to	quickly	
report	febrile	illnesses	and	to	disclose	their	
travel	histories	to	healthcare	providers.
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z Evidence summary
Malaria is a parasitic infection that 
causes significant morbidity and mor-
tality worldwide, with more than 500 
million people becoming severely ill 
every year.2 For pregnant women, 
malarial infection can be severe, with 
high fevers, chills, and anemia lead-
ing to increased risk of poor maternal 
and fetal outcomes—including death. 
Pregnant women are also more likely to 
become infected and to develop more 
severe disease—they attract twice as 
many mosquitoes as nonpregnant 
women and have a relative immuno-
suppression.3 
Clinical commentary
Evidence-based answer
fast track
Urge women to 
delay travel to 
malaria-endemic 
areas until after 
pregnancy
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Chemoprophylaxis lowers rates  
of maternal infection
Although prophylaxis for pregnant pa-
tients traveling to malarial regions is a 
public concern, data for decision-mak-
ing must be extrapolated from the avail-
able evidence, which is based primarily 
on women living in endemic areas. In 
a Cochrane systematic review, antima-
larials were found to decrease the inci-
dence of maternal infections (relative 
risk [RR]=0.27; 95% confidence interval 
[CI], 0.17–0.44) and reduce maternal 
anemia (RR=0.62; 95% CI, 0.50–0.78) 
in low-parity women—ie, during a first 
or second pregnancy.3 
In low-parity women, these drugs 
were also found to decrease perinatal 
death (RR=0.73; 95% CI, 0.53–0.99) 
and low birth weight (RR=0.57; 95% 
CI, 0.46–0.72) associated with ma-
larial infection. When used in all parity 
groups, antimalarials were somewhat 
less effective, yet still reduced maternal 
infections (RR=0.53; 95% CI, 0.33–
0.86); the effects were similar with all 
antimalarials tested.3,4 
Chloroquine, mefloquine are safe 
in pregnancy, doxycycline is not
While chemoprophylaxis in pregnancy 
appears efficacious, a major question 
remains—which agents are safest for 
both the woman and fetus? Some drugs 
routinely used in nonpregnant individu-
als should not be offered to pregnant 
women because of known direct effects 
on the fetus. Doxycycline is teratogenic, 
and primaquine poses a significant risk of 
fetal intravascular hemolysis in G6PD-
deficient fetuses.5 Other drugs, such as 
atovaquone/proguanil and artesunate, are 
Antimalarials for prophylaxis:  
Chloroquine, mefloquine are best choices during pregnancy
   PrEgnAnCy  
Drug EffiCACy SAfETy ClASS* AvAilAbiliTy
Chloroquine	 Good	 excellent	 C	 Worldwide
Chloroquine/proguanil	 Good	 excellent	 C	 Worldwide
mefloquine	 excellent	 Good		 C	 Worldwide
Quinine	 excellent	 Good	 C†	 Worldwide
Atovaquone/proguanil	 excellent	 Good	 C	(poorly	 Worldwide	
	 	 	 studied)
Artesunate	 excellent	 Good	 n/a	 asia,	africa,	limited	in	uK,		
	 	 	 	 not	in	us
Primaquine	 Good	 Fair	 C‡	 Worldwide
Doxycycline	 excellent	 Fair	 D	 Worldwide	
	 	 	 (teratogenic)
Sulfadoxine/pyrimethamine	 Fair	 Poor	 C	 Worldwide,	but	restricted	in	us
Note: Prescribers	and	patients	are	urged	to	refer	to	the	CDC	reference	about	pregnancy	in	malaria	(wwwn.cdc.
gov/travel/contentMalariaPregnantPublic.aspx)	and	to	specific	country	information	regarding	sensitivities	of	malaria	
(wwwn.cdc.gov/travel/destinationlist.aspx).	
*	Pregnancy class C:	animal	reproduction	studies	have	shown	an	adverse	effect	on	the	fetus	and	there	are	no	
adequate	and	well-controlled	studies	in	humans,	but	potential	benefits	may	warrant	use	of	the	drug	in	pregnant	
women,	despite	potential	risks.	
*	Pregnancy class D:	There	is	positive	evidence	of	human	fetal	risk	based	on	adverse	reaction	data	from	investiga-
tional	or	marketing	experience	or	studies	in	humans,	but	potential	benefits	may	warrant	use	of	the	drug	in	pregnant	
women,	despite	potential	risks.
†	Monitor	patients	for	maternal	hypoglycemia.
‡	There	is	no	evidence	of	teratogenicity,	but	primaquine	is	associated	with	fetal	intravascular	hemolysis.
table
Give pregnant 
women verbal and 
written counsel on 
avoiding exposure 
by using   
permethrin-treated 
netting and insect  
repellant
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not well studied in pregnancy, and there-
fore are not recommended for use unless 
other options are not available.2,6 
Among drugs that are well studied 
and without known direct fetal-damaging 
effects, adverse drug reaction profiles can 
guide use based on disease prevalence and 
drug-resistance patterns. 
• Chloroquine is widely used because 
it is inexpensive and well tolerated, with 
only pruritus, mouth ulcers, and gastro-
intestinal upset as the most common ad-
verse effects.
• mefloquine is usually well tolerated, 
but can cause dose-related neuropsychi-
atric effects; it is contraindicated in those 
with a history of epilepsy or psychiatric 
disease. 
• Sulfadoxine and pyrimethamine are 
not normally used as prophylaxis for any 
patient, due to the risk of toxic epider-
mal necrolysis and Stevens-Johnson syn-
drome, and the possible risk of jaundice 
and kernicterus if used in the third trimes-
ter of pregnancy. 
• Quinine, which can be used for treat-
ment or prophylaxis, may cause hypogly-
cemia, an effect that is more pronounced 
during pregnancy and requires close 
monitoring of blood glucose levels.5,7 
Given these reaction profiles, chlo-
roquine or mefloquine are usually the 
best choice with their superior safety 
and efficacy. 
Recommendations from others
The World Health Organization (WHO) 
recommends pregnant women avoid 
travel to malarial regions. If travel is re-
quired, WHO recommends chloroquine 
as first-line prophylaxis in pregnancy 
(plus proguanil if the region exhibits 
emerging chloroquine resistance). In 
areas with proven chloroquine resis-
tance, mefloquine is the drug of choice. 
Other antimalarials—such as quinine, 
pyrimethamine, sulfadoxine, and artesu-
nate—should not be withheld if the pre-
ferred drugs are not available, or if the 
infection is life-threatening.2 
The Centers for Disease Control 
and Prevention (CDC) also recommends 
avoiding travel to malaria-endemic re-
gions during pregnancy, but if travel is 
necessary, the CDC advises use of chlo-
roquine (or mefloquine in regions with 
chloroquine resistance). The CDC dis-
courages the use of atovaquone/progua-
nil, doxycycline, and primaquine, due to 
known adverse fetal effects or inadequate 
experience in pregnancy.6   n
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Malaria prophylaxis in pregnancy
The World Health 
Organization  
recommends  
chloroquine  
as first-line  
prophylaxis  
in pregnancy 
Chloroquine	and	mefloquine	are	the	safest	antimalarials	
for	 use	 in	 pregnant	 women,	 but	 	 personal	 protection	
measures	 are	 also	 critical.	 above,	 an	 Anopheles 
stephensi mosquito	 expelling	 a	 droplet	 of	 blood	 from	
its	abdomen	after	having	engorged	itself	on	its	human	
host’s	blood.	(Source:	CDC.)
figure
Best protection:  
Avoidance 
